France· FR:68309829
CELOCURINE 50 mg/ml, solution injectable
A suxamethonium product containing chlorure de suxaméthonium, registered in France by NEURAXPHARM FRANCE. The same ATC class is registered in 14 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Suxamethonium is registered in 14 of 19 countries.
Countries holding a registration under ATC M03AB01 (suxamethonium), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 7 of them publish a price we can compare per daily dose
Suxamethonium · ATC M03AB01
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- CHLORURE DE SUXAMÉTHONIUM
- Manufacturer
- NEURAXPHARM FRANCE
- Country
- France (FR)
- ATC code
- M03AB01
- ATC class
- Suxamethonium
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip13340095630444810 ampoule(s) en verre de 2 ml
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
74 interactions on record for suxamethonium.
Graded by severity as the source publishes them — 14 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Suxamethonium · interactions on record
74 records
- 14 severe
- 56 moderate
- 4 minor
Most severe, free to view
- NeomycinA07AA01severe
- StreptomycinA07AA04severe
- Polymyxin BA07AA05severe
- ParomomycinA07AA06severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under M03AB01
Suxamethonium, as other registers publish it.
- United KingdomAnectine 100mg/2ml solution for injection ampoulesAspen Pharma Trading Ltd
- BelgiumCelocurine 100 mg/2 mlNeuraxpharm Belgium
- BelgiumCelocurine 500 mg/10 mlNeuraxpharm Belgium
- PolandChlorsuccillinBausch Health Ireland Ltd.
- GermanyLysthenonEvolan Pharma Ab
- GermanyLysthenonEvolan Pharma Ab
- NorwayLysthenonTakeda
- IrelandMurexal 10 mg/mL solution for injection in pre-filled syringeLaboratoire Aguettant
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/304e4d36-c21e-4dd3-8048-26a952952d4b GET /v1/drugs/304e4d36-c21e-4dd3-8048-26a952952d4b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "68309829",
"date_amm": "2001-05-11",
"type_amm": "Procédure nationale",
"numero_ue": null,
"substance": "CHLORURE DE SUXAMÉTHONIUM",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution injectable",
"voies_administration": "intraveineuse",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about suxamethonium.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.